About Neotract
Neotract is a Healthcare company based in Mountain View (United States) founded in 2004, and was acquired by Teleflex Medical in September 2017. Minimally invasive devices in urology. Neotract has raised $137.96 million across 9 funding rounds from investors including Teleflex Medical, CRG and Johnson & Johnson Innovation – JJDC. The company has 119 employees. Neotract offers products and services including Support Center, NS Lookup Tool, Web Browser Details Checker, Site Down Checker, and IP Address Checker. Its focus areas include Life Sciences, Genitourinary Disorders, Medical Devices and Therapeutics. Its legal entity is NEOTRACT INC. Its competitors include Zenflow, Urotronic and Rivermark; 3 of its 3 listed competitors have raised funding.
Company details
NeoTract develops surgical devices for urological disorders. The first product is UroLift, a minimally invasive device to treat lower urinary tract symptoms due to Benign Prostatic Hyperplasia (BPH). The permanent UroLift implant is placed transurethrally. It lifts the enlarged prostate tissue out of the way so it no longer blocks the urethra.
- Headquarters Mountain View, United States
- Employees 119
- Stage Acquired
- SectorsHealthcare
- Website neotract.com
- Social LinkedIn Facebook
- Acquired by Teleflex Medical (Sep 2017)
- Legal Name Neotract Inc
- Total Equity Funding$137.96M (USD)
in 9 rounds
- Latest Funding Round$12.82M (USD), Series C
Jan 2017
- InvestorsTeleflex Medical
& 4 more
- Employee Count119
- Acquired byTeleflex Medical
(Sep 2017)
Products & Services of Neotract
Neotract offers a comprehensive portfolio of products and services, including Support Center, NS Lookup Tool, Web Browser Details Checker, Site Down Checker, and IP Address Checker.
Platform for submitting and managing support requests
Tool to check domain name system records online
Utility to verify web browser configurations
Service to test if a website is accessible
Tool to display and analyze user IP addresses
Funding Insights of Neotract
Neotract has successfully raised a total of $137.96M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $12.82 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $137.96M
- Total Rounds 9
- Last Round Series C — $12.82M
- Investors Count 4
All 9 funding rounds of Neotract with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $12.82M | Series C | – | – | – |
| Dec 2016 | $80M | Debt – Conventional | – | – | |
| Jan 2014 | $50.56M | Series C | – | – | – |
| Feb 2011 | $26M | Series B | – | – | – |
| Oct 2009 | $28.11M | Series B | – | Johnson & Johnson Innovation – JJDC | |
| Oct 2009 | Series B | – | – | ||
| May 2008 | $8.48M | Series A | – | – | |
| Mar 2006 | $12M | Series A | – | – | – |
| Jun 2005 | Seed | – | – |
5 investors in total: 5 institutional.
Investors in Neotract
Neotract has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Teleflex Medical, CRG and Johnson & Johnson Innovation – JJDC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CRG is recognized as a premier healthcare investment partner. | crglp.com | Houston, United States | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
PE firm backed by quilvest group | quilvestprivateequity.com | Las Condes, Chile | ||
Provider of medical devices for emergency medicine and various health conditions | 1943 | teleflex.com | Wayne, United States |
Investor details for Neotract
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Neotract
4 dated milestones of Neotract across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Neotract is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $12.8M.
- Exit Acquired by Teleflex Medical.
Competitors of Neotract
Neotract has 3 listed competitors in our database, 3 of them funded. They include Zenflow, Urotronic and Rivermark.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| zenflow.com | 2014 | Palo Alto, United States | $48M | 25 | A device is developed to treat urinary obstruction from BPH. | |
| urotronic.com | 2015 | Plymouth, United States | $47.05M | 18 | Urethral stricture treatment devices are developed by Urotronic. | |
| rivermarkmedical.com | 2021 | Milwaukee, United States | $34.16M | Medical device for benign prostatic hyperplasia treatment is developed. |
Detailed competitors of Neotract
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Neotract
Websites that share an audience with Neotract (neotract.com).
Websites whose visitors overlap most with Neotract. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| urolift.com | 100% | 59.4K | #629,453 | View details | |
gbmc.org | gbmc.org | 57% | #139,131 | – |
Top companies in Genitourinary Disorders
3 companies that operate in the same segment as Neotract (Genitourinary Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neotract
Complete news archive for Neotract
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neotract
Neotract was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Neotract is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Neotract is a funded company, having raised a total of $137.96M across 9 funding rounds to date.
Neotract has 119 employees.
NeoTract develops surgical devices for urological disorders. The first product is UroLift, a minimally invasive device to treat lower urinary tract symptoms due to Benign Prostatic Hyperplasia (BPH). The permanent UroLift implant is placed transurethrally. It lifts the enlarged prostate tissue out of the way so it no longer blocks the urethra.
Neotract offers Support Center, NS Lookup Tool, Web Browser Details Checker, Site Down Checker, and IP Address Checker.
Neotract has 5 investors. Key investors include Teleflex Medical, CRG, Johnson & Johnson Innovation – JJDC, NEA, and Quilvest Private Equity.
Neotract operates through Neotract Inc.
Yes. Neotract was acquired by Teleflex Medical in September 2017.